Clinical Edge Journal Scan

Potential moderators of response to behavioral treatment for migraine prophylaxis


 

Key clinical point: Disability, anxiety, and comorbid mental disorders moderated the long-term effect of migraine-specific cognitive behavioral therapy (miCBT) or relaxation training (RLX) on headache days in patients with migraine, with those having higher and lower burden benefitting more from miCBT and RLX, respectively.

Major finding: Patients with higher headache-related disability ( B −0.41; P = .047), anxiety ( B −0.66; P = .056), and comorbid mental disorders ( B −4.98; P = .053) benefited more from miCBT, whereas those with relatively lower headache-related disability and anxiety and without any comorbid mental disorder benefited more from RLX at 12 months of follow-up.

Study details: This secondary analysis of an open-label randomized controlled trial included 121 patients with migraine who were randomly assigned to the miCBT (n = 40), RLX (n = 41), or waiting-list control (n = 40) group.

Disclosures: This study received no specific funding. C Gaul and E Liesering-Latta declared receiving consulting and lecture honoraria from various sources. C Gaul declared serving as an honorary secretary of the German Migraine and Headache Society. The other authors declared no conflicts of interest.

Source: Klan T et al. Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial. Cephalalgia. 2023;43(6) (Jun 8). Doi: 10.1177/03331024231178237

Recommended Reading

Cannabis RCT shows efficacy, AEs in migraine
Migraine ICYMI
Migraine device expands treatment possibilities
Migraine ICYMI
Can a puff of cool air up the nose stop acute migraine?
Migraine ICYMI
Anti-CGRP monoclonal antibody offers relief from migraine and comorbid depression
Migraine ICYMI
Migraine treatment with rimegepant linked to reduced barbiturate use
Migraine ICYMI
Prodrome treatment with ubrogepant prevents migraines
Migraine ICYMI
What is the proper treatment for posttraumatic headache? Expert debate
Migraine ICYMI
Commentary: Refractory chronic migraine treatment, July 2023
Migraine ICYMI
Migraine elevates risk for ischemic stroke in men and women with migraine
Migraine ICYMI
Study supports use of BP-lowering medications for prevention of episodic migraine
Migraine ICYMI